NCT00393965 is a Phase 1 clinical trial of MPC-6827 in Brain Neoplasms, sponsored by Myrexis Inc..

Who is sponsoring NCT00393965?

NCT00393965 is sponsored by Myrexis Inc..

What drugs are being tested in NCT00393965?

Interventions in NCT00393965: MPC-6827.

What condition does NCT00393965 study?

NCT00393965 studies Brain Neoplasms.

Is NCT00393965 still recruiting?

NCT00393965 is currently completed. Last updated 11 February 2008.

Last reviewed 2008-02-11 · How we verify

NCT00393965

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Open Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of MPC-6827 Administered IV Weekly X 3, Repeated Every 28 Days, in Subjects With Refractory Brain Metastases

Completed Phase 1 Last updated 11 February 2008

What this trial tests

Phase 1 trial testing MPC-6827 in Brain Neoplasms in 18 participants. Completed in 1 February 2008.

Timeline

1 December 2005

Primary endpoint
1 August 2007

1 February 2008

Quick facts

Lead sponsor	Myrexis Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	1 December 2005
Primary completion	1 August 2007
Estimated completion	1 February 2008
Sites	1 location across United States

Drugs / interventions tested

MPC-6827 — full drug profile →

Conditions studied

Brain Neoplasms — all drugs for Brain Neoplasms →

Sponsor

Myrexis Inc. — full company profile →

Who can join

18 and older, any sex, with Brain Neoplasms. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Maximum Tolerated Dose
Time frame: 1 year
Pharmacokinetics
Time frame: 1 year

Sponsor's own description

Phase 1, Multiple dose Study of MPC-6827 in Subjects with Refractory Brain Metastases.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Brain Neoplasms

Currently open trials in the same condition.

NCT07272616 — Detection of Brain Metastases Using a Novel Gadolinium-Weighted MRI Sequence: A Prospective Comparison · recruiting
NCT07426848 — OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour Patients · NA · recruiting
NCT07111182 — Intraoperative Fluorescence-Guided Aspirate Tissue Monitoring of 5-ALA During Brain Tumor Surgery · NA · recruiting
NCT07238322 — [18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes · active not recruiting
NCT06165653 — Guided Meditation During Radiation Therapy for Brain Tumors · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00393965 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Myrexis Inc.
Last refreshed: 11 February 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00393965.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing